INT264798

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.40
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 9
Total Number 9
Disease Relevance 2.95
Pain Relevance 1.27

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (GLP1R) plasma membrane (GLP1R) signal transducer activity (GLP1R)
Anatomy Link Frequency
neurons 1
GLP1R (Homo sapiens)
Pain Link Frequency Relevance Heat
Central nervous system 3 99.80 Very High Very High Very High
Potency 4 98.88 Very High Very High Very High
adenocard 5 97.96 Very High Very High Very High
agonist 121 94.56 High High
antagonist 91 88.52 High High
tolerance 6 84.48 Quite High
cytokine 2 82.04 Quite High
nud 7 74.64 Quite High
headache 9 18.60 Low Low
depression 6 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Targeted Disruption 3 98.08 Very High Very High Very High
Pancreatitis 13 95.92 Very High Very High Very High
Disease Progression 17 94.28 High High
Diabetes Mellitus 235 91.80 High High
Impaired Glucose Tolerance 5 85.12 High High
Vomiting 66 84.76 Quite High
Death 1 82.80 Quite High
Hypoglycemia 54 80.76 Quite High
Weight Loss 24 80.00 Quite High
Apoptosis 6 75.80 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
GLP-1 binds to its receptor on hypothalamic neurons and stimulates satiety.
GLP-1 Binding (binds) of in neurons
1) Confidence 0.40 Published 2010 Journal Pediatr Nephrol Section Body Doc Link PMC2874027 Disease Relevance 0.47 Pain Relevance 0.08
It binds to highly specific GLP-1 receptors that belong to the G-protein coupled receptors [6].
GLP-1 Binding (binds) of
2) Confidence 0.40 Published 2010 Journal Pediatr Nephrol Section Body Doc Link PMC2874027 Disease Relevance 0.36 Pain Relevance 0.05
As it is the free fraction of liraglutide that interacts with GLP-1 receptors, it is possible that the pharmacodynamic effect will be enhanced in the setting of reduced circulating albumin concentrations.
GLP-1 Binding (interacts) of
3) Confidence 0.34 Published 2010 Journal British Journal of Clinical Pharmacology Section Body Doc Link PMC2997321 Disease Relevance 0.35 Pain Relevance 0
Taspoglutide shows high binding affinity to the human GLP-1 receptor and assessment of its relative activity on cyclic adenosine monophosphate stimulation in cells expressing the GLP-1 receptor suggests that it is fully active [4].
GLP-1 receptor Binding (affinity) of associated with adenocard
4) Confidence 0.28 Published 2010 Journal Diabetic Medicine Section Body Doc Link PMC2948428 Disease Relevance 0.24 Pain Relevance 0.09
Furthermore, the exenatide antibodies do not cross-react with human GLP-1 [24].
GLP-1 Binding (react) of
5) Confidence 0.26 Published 2010 Journal Pediatr Nephrol Section Body Doc Link PMC2874027 Disease Relevance 0.99 Pain Relevance 0.04
Some researchers have shown that both of them (GLP-1 and EX) bind and activate the pancreatic GLP-1 receptor (GLP-1R) with similar affinity and potency[13–15].
GLP-1R Binding (bind) of associated with potency
6) Confidence 0.09 Published 2010 Journal Indian Journal of Pharmaceutical Sciences Section Body Doc Link PMC2883206 Disease Relevance 0.31 Pain Relevance 0.15
Although the modulator enhances the binding of GLP-1 it does not detectably enhance the signaling activity of the peptide.


GLP-1 Binding (binding) of
7) Confidence 0.05 Published 2007 Journal Current Neuropharmacology Section Body Doc Link PMC2656815 Disease Relevance 0.10 Pain Relevance 0.30
This nonpeptide ligand enhances the binding of [125I]GLP-1 to the GLP-1 receptor and directly activates the receptor, with potency of approximately 100nM.
GLP-1 receptor Binding (binding) of associated with potency
8) Confidence 0.03 Published 2007 Journal Current Neuropharmacology Section Body Doc Link PMC2656815 Disease Relevance 0.07 Pain Relevance 0.29
This nonpeptide ligand enhances the binding of [125I]GLP-1 to the GLP-1 receptor and directly activates the receptor, with potency of approximately 100nM.
GLP-1 Binding (binding) of associated with potency
9) Confidence 0.03 Published 2007 Journal Current Neuropharmacology Section Body Doc Link PMC2656815 Disease Relevance 0.07 Pain Relevance 0.29

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox